← All Inspiremd, INC filings

Inspiremd, INC 10-K annual reports

Annual reports — audited financials, the full risk-factor list, and management’s account of the year.

NASDAQ
NSPR
Inspiremd, INC
10-K: InspireMD Reports Positive C-GUARDIANS Trial Results, Eyes FDA Approval in 2025
InspireMD's C-GUARDIANS trial demonstrates positive one-year follow-up results, supporting a PMA submission for potential FDA approval of the CGuard Prime carotid stent system in the first half of 2025.
NASDAQ
NSPR
Inspiremd, INC
10-K: InspireMD, Inc. Details Share Structure and Regulatory Landscape in Annual Filing
InspireMD's annual 10-K filing outlines its capital structure, stock details, and regulatory compliance, highlighting its focus on the CGuard stent system and future growth.